The condition, known as PCOS, was first described in 1935 by Stein and Leventhal, who noted the presence of enlarged ovaries in obese, hirsute women with cycle disorders [22]. Since that time, PCOS has been found to be a complex condition with contingent etiopathogenesis and heterogeneous clinical signs. The diagnosis has evolved over time, and its development is subject to controversy [23]-[26]. These controversies are exemplified by the historical underrepresentation of PCOS in adolescent girls in France, where it was considered rare or exceptional, in contrast to its predominance as the primary cause of peri-pubertal hyperandrogenism in Anglo-Saxon countries. This paradox underscores the existing uncertainties surrounding the boundaries of the syndrome.

In clinical practice, the diagnosis of PCOS in adult women is made using clinical and paraclinical criteria, as defined by the consensus of multiple learned societies. The three criteria that are generally taken into account are as follows: chronic oligo-anovulation (OA), clinical and/or biological hyperandrogenism (HA), and the presence of polycystic ovaries on ultrasound (PCOS) [26]. The following text is intended to provide a comprehensive overview of the subject matter.

Clinically, the condition known as oligo-anovulation is suspected in patients with irregular menstrual cycles. In the field of gynecology, menstrual cycles are classified as irregular if they occur less than 21 days or more than 35 days apart, or if there are fewer than eight cycles per year. This classification is particularly relevant for women who are more than three years past their gynecological age. Menstrual irregularities are regarded as physiological in the year following menarche. In the three-year period following menarche, cycle disorders are characterized by cycles that are either shorter than 21 days or longer than 45 days, or that occur with a frequency of fewer than four cycles per year.

Hyperandrogenism manifests clinically through acne and hirsutism. Alopecia is an uncommon manifestation of hyperandrogenism. Other clinical signs of hyperandrogenism include seborrhea, hyperhidrosis, and hidradenitis suppurativa [9]. In PCOS, acne is severe, often has an early onset, and affects at least two areas of the body. It manifests as microcysts, comedones, and papules or pustules. It is persistent, male-pattern (chin, neck, chest) with increased facial hair, and responds poorly to local treatments [27]. Hirsutism is abnormal hair growth due to its androgen-dependent location in women [28]. It is clinically defined by the modified Ferriman-Gallway score, which assesses hair growth in women in areas that are normally hairless (upper lip, face, chin, back, chest, linea alba, inguinal folds, inner and back of the thighs). However, the use of the Ferriman-Gallway score remains controversial for dark or olive skin tones [29].

The diagnosis of biological hyperandrogenism is confirmed by an increase in total and/or free testosterone [30]. In the context of PCOS, the absence of hyperandrogenism detection through blood tests has been documented in 20 to 60% of cases [31]. In instances where testosterone or free testosterone levels are not elevated, the consideration of additional testing for androstenedione and dehydroepiandrosterone sulfate (DHEAS) may be contemplated, taking into account the lower specificity of these assessments and the natural decline in DHEAS levels associated with aging [26]. The measurement of 17-hydroxyprogesterone (17-OHP) is primarily utilized to exclude alternative etiologies of hyperandrogenism [16].

The ultrasound criteria for PCOS have evolved in tandem with advancements in ultrasound machines and endovaginal probes. The confirmation of PCOS is contingent upon the presence of at least 20 follicles per ovary in at least one ovary, utilizing an endovaginal probe operating at a frequency exceeding 8 MHz. In optimal conditions, the utilization of Sonography-based Automated Volume Count (SonoAVC) [32] is strongly advised. The number of follicles per ovarian cross-section (Follicle Number Per Cross-Section, FNPS) thus offers a practical and reliable alternative for refining the evaluation of ultrasound criteria in the diagnosis of PCOS [26].

This approach enables a more precise analysis of ovarian morphology, particularly in cases where technical constraints or operator proficiency impede comprehensive visualization of the ovaries. In order to diagnose OPK, the presence of at least 10 follicles per ovarian slice, in at least one ovary, is necessary. The following text is intended to provide a comprehensive overview of the subject matter. In instances where a less powerful ultrasound scanner is employed, the presence of an ovarian volume exceeding 10 milliliters or the measurement of an ovarian surface area along its longest axis can facilitate the ultrasound diagnosis of OPK. With regard to the peripheral distribution of follicles and ovarian density, these have been excluded from the consensus definition because they are non-discriminatory and do not allow for a reliable diagnosis [33].

The initial step in diagnosing PCOS is to exclude other conditions that may present with comparable clinical, biological, and ultrasound manifestations. These include congenital adrenal hyperplasia, nonclassical 21-hydroxylase deficiency, thyroid disorders, Cushing’s syndrome, hyperprolactinemia, and androgen-secreting tumors. It is imperative to consider the potential effects of medications that may mimic the symptoms of PCOS, including synthetic progestogens, anabolic steroids, and valproic acid (Depakine®), an anticonvulsant medication that is well-known for its hormonal implications [26].

Another factor that is not listed in the diagnostic criteria but is common in PCOS is insulin resistance [6][34]-[36]. Insulin resistance and hyperinsulinism are two conditions found in at least 50% of PCOS cases [35].

Hyperinsulinism has been demonstrated to induce the activation of steroidogenesis in small follicles, resulting in elevated levels of ovarian androgens. Insulin has been demonstrated to impede SHBG, augment the bioavailability of testosterone in the circulation, and exacerbate the clinical manifestations of HA [35][36]. When evaluating PCOS, the issue of insulin resistance is paramount, as it is often implicated in the pathophysiology of the syndrome. Among the tools available for assessing insulin resistance, the HOMA (Homeostasis Model Assessment) index appears to be the most widely used in clinical and epidemiological studies [19]. The HOMA index, a calculation derived from fasting blood glucose and insulin levels, offers a straightforward and cost-effective approach to estimating pancreatic function and insulin sensitivity. This approach is particularly valuable in the early identification of insulin resistance in adolescent girls with PCOS, even in the absence of overt clinical signs such as obesity [37].

Waist circumference measurement, in conjunction with the waist-to-height ratio, serves as a crucial predictor of insulin resistance and metabolic risk. Waist circumference greater than 80 centimeters, or a waist-to-height ratio equal to or greater than 0.52, has been demonstrated to correlate well with an increased risk of insulin resistance and cardiometabolic complications. Moreover, it is imperative to assess glucose tolerance, commencing with a fasting blood glucose measurement, particularly in adolescents with a body mass index (BMI) greater than 25 kg/m². In the event of abnormalities or additional risk factors, an oral glucose tolerance test (OGTT) should be performed to detect possible glucose intolerance or type 2 diabetes [38].

In light of the considerable phenotypic variability observed among individuals diagnosed with PCOS, multiple criteria have been established by prominent scientific societies to streamline the diagnostic process. The inaugural expert conference on PCOS took place in 1990, under the auspices of the National Institutes of Health (NIH). By consensus, the association of HA with OA in the diagnosis of PCOS was retained, with no reference to OPK [11]. Subsequently, the Rotterdam criteria, established by the European Society of Human Reproduction and Embryology and the American Society for Reproductive Medicine (ESHRE/ASRM 2003), included, in addition to the two aforementioned criteria, the presence of OPK on ultrasound examination. However, it was specified that the presence of two of the three criteria was sufficient to make the diagnosis, thus leaving open the possibility of diagnosing PCOS without HA [32]. In 2006, at a conference organized by the Androgen Excess Society and PCOS Society (AE-PCOS), experts convened to re-evaluate the conclusions reached in 2003. They concluded that HA was a prerequisite for diagnosing PCOS. The second criterion remained either OPK and/or OA [39]. The following text is intended to provide a comprehensive overview of the subject matter.

In 2012, the National Institutes of Health (NIH) convened a meeting to deliberate the merits and drawbacks of the prevailing diagnostic criteria, which were grounded in the principles of evidence-based medicine [40]. Two major recommendations were formulated as a result of this conference. The initial proposal pertained to a modification in the nomenclature of the syndrome. It was proposed that the nomenclature should incorporate terms reflecting the complexity of its pathophysiology and related complications. Among the various proposals put forth was the concept of “reproductive metabolic syndrome.” Despite the fact that this designation suggested impaired reproductive and metabolic health, thereby alluding to the pathophysiology and clinical manifestation of PCOS, it was not adopted.

The second recommendation validated the utilization of the Rotterdam criteria for diagnosis, encompassing the 1990 NIH conference diagnosis and the 2006 AE-PCOS diagnosis, while also providing a comprehensive description of the four PCOS phenotypes, including one devoid of AH [26][40]. The reemergence of PCOS in the absence of HA was substantiated by the inadequacy of clinical and biological assessment methodologies, which could result in false negatives [40]. The diagnostic criteria for PCOS, as established by consensus conferences and delineated according to the four established phenotypes of the syndrome, are delineated in Tables 1and 2, respectively.

Table 1.Diagnostic criteria for PCOS according to consensus conferences. [16][26][41]

Table 2. PCOS phenotypes. (NIH 2012/International PCOS Guidelines 2018)

PCOS = polycystic ovaries syndrome

In 2023, the International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (IGAM-PCOS) proposed the most recent expert opinions and guidelines for PCOS [26]. A simplified three-step approach was described for diagnosing PCOS. The initial step in this process is to ascertain the regularity or irregularity of the cycles. In the event of irregular cycles, a clinical examination is indicated to ascertain the presence of AH. The presence of clinical AH is indicative of PCOS, provided that other conditions have been excluded [42]. In the absence of clinical hypothyroidism (HA), investigation of biological hypothyroidism (HA) is recommended, and if present, PCOS can be considered a likely diagnosis after ruling out other conditions. In instances where cycles are irregular in the absence of clinical and biological HA, an endovaginal ultrasound should be performed in sexually active women. In the case of sexually inactive adolescents, it is necessary to wait and reassess at a later date. However, it is imperative to consider these patients as potentially being at risk of PCOS until an ultrasound scan can be performed under optimal conditions [13][16]. The Rotterdam criteria continue to be valid, albeit with some modifications to their validation process [15]. Since 2023, the IGAM-PCOS has authorized the measurement of AMH as a diagnostic marker for PCOS in adults only, with the same value as the follicular count on ultrasound [26].

In instances of anovulation and hyperandrogenism, ultrasound and AMH testing are not necessary for diagnosis. Moreover, it is recommended that AMH testing and ultrasound imaging not be used concurrently to avoid overdiagnosis [26].

3.2.1. Diagnosis of PCOS in Adolescents

The absence of a consensus on the definition of PCOS in adolescents hinders the establishment of diagnostic criteria and, consequently, the development of effective treatment strategies [22]. The diagnostic criteria employed for adult women may be subject to misinterpretation in adolescents due to transient physiological phenomena associated with their biological transition [23][25]. Hyperandrogenism, cycle disorders, polycystic ovaries, insulin resistance, and weight gain are all common conditions associated with PCOS that are present in adolescence. However, these abnormalities, which are considered temporary, persist in some adolescents and develop into full-blown PCOS.

HA, which is one of the signs of PCOS, is found in 3% - 20% of adolescents [43]. It is possible that this HA is the result of the immaturity of the hypothalamic-pituitary-ovarian axis during adolescence (HHO) [26]. Hirsutism and moderate to severe acne are the most common skin signs of PCOS. They have a negative impact on the self-esteem and social life of adolescents at a time when physical appearance is of paramount importance for their integration into society. Acne is a physiological manifestation of puberty. It is linked to the relative physiological HA of this period. This functional HA is the result of a hormonal imbalance in favor of androgens.

During adrenarche, which occurs between the ages of 8 and 10 in girls, there is a tripling of adrenal androgen concentration. The increase in ovarian androgens contributes to the increase in circulating androgens. Conversely, the absence of estrogen and progesterone during the initial cycles, which frequently manifest as anovulatory, exacerbates this HA. However, this imbalance is counterbalanced as the hypothalamic-pituitary-ovarian axis attains maturity [26]. However, the clinical presentation of acne is pathological when it occurs before puberty or in the form of moderate to severe acne with comedones at the onset of puberty, or moderate to severe inflammatory acne during perimenarche. Alopecia, which is also a manifestation of hyperandrogenism, has not yet been studied in adolescent girls with PCOS [31].

In the majority of adolescent girls, androgen levels attain adult levels around the time of menarche, which occurs between the ages of 12 and 15. The upper limit of androgen levels in this age group is 0.5 ng/mL (1.7 nmol/L). It is important to acknowledge that the use of estrogen-progestogen pills, an increase in the free fraction of testosterone, and a decrease in sex hormone-binding globulin (SHBG) are all confounding factors. With regard to oligomenorrhea in adolescents, it is considered physiological in the year following menarche. This phenomenon can be attributed to the immaturity of the hypothalamic-pituitary-ovarian axis, the hormonal regulation of which is a gradual process that precedes the establishment of regular ovulatory cycles [34]-[36]. However, it would be a mistake to consider all cycle irregularities as normal in adolescents. In the three-year period following menarche, cycle disorders are characterized by cycles that are either less than 21 days or more than 45 days in duration, or that occur with a frequency of fewer than four cycles per year. Indeed, the persistence of spaniomenorrhea for a period exceeding one year or more than two years following menarche, or primary amenorrhea after the age of 15 or 16, i.e., three years after the onset of breast development, has been identified as a contributing factor to ovarian dysfunction, glucose regulation disorders, and PCOS [37][44]. This should prompt diagnostic steps to determine the underlying cause.

With regard to the well-described ultrasound criteria for PCOS in adults, it is not recommended until after eight years of gynecological age in adolescents. Indeed, the ultrasound diagnosis of PCOS involving the use of a vaginal probe is not possible in sexually inactive adolescents. The suprapubic approach, however, poses challenges in the estimation of ovarian follicles due to its inherent low spatial resolution [25]. The micro-polycystic ultrasound appearance of the ovaries manifests with a high incidence during adolescence. Furthermore, an increase in gonadotropin physiological hyperstimulation results in increased volume and size of the ovaries, which are proportionally larger than in adults and thus become an additional confounding factor [39][40]. However, the use of ultrasound can help rule out underlying uterine or ovarian pathologies [45]. In contrast to adults, AMH testing is not recommended for adolescents.

In adolescent girls diagnosed with metabolic syndrome, insulin resistance is frequently observed and results from compensatory hyperinsulinism. The latter results in a decrease of approximately 50% in insulin sensitivity, leading to increased insulin production to maintain glycemic homeostasis. However, this hyperinsulinemia appears to be transient and may normalize in adulthood, suggesting that hormonal changes associated with puberty influence the regulation of insulin sensitivity [25][42]. Excess insulin potentiates stimulation of the hypothalamic-pituitary-ovarian axis, leading to increased androgen production by theca cells. This, in turn, disrupts follicular maturation and promotes the clinical signs of PCOS. Increased AMH levels are indicative of a high follicular reserve, which is associated with excessive recruitment of follicles without adequate maturation.

It has been demonstrated that certain anamnestic factors have the potential to serve as a catalyst for the diagnosis of PCOS in adolescence. These factors may include a family history of PCOS and/or metabolic diseases. Leibel et al. reported that the majority of adolescent girls with PCOS either have a mother with PCOS or a father with metabolic syndrome [46]. The diagnosis may also be considered in adolescents born with intrauterine growth retardation or macrosomia, as well as those who have experienced early onset of pubic and axillary hair growth [47]. However, the age at menarche appears to be later in thin adolescents with PCOS (body mass index [BMI] < 25 kg/m²).

In adolescents, a diagnosis of PCOS is made on the basis of persistent clinical, biological, and ultrasound abnormalities, taking into account the physiological characteristics of this period of life. When these abnormalities persist for more than two years after menarche, a diagnosis of PCOS can be confirmed in the adolescent, while remaining vigilant about differential diagnoses and physiological variations in puberty.

The Paediatric Endocrine Society, ESHRE, the American Society for Reproductive Medicine (ASRM), and the Australian National Health Medical Research Council (NHMRC) have concluded that PCOS should be suspected in adolescents with irregular menstrual cycles associated with hyperandrogenism. However, in adolescents, the presence of regular cycles does not preclude the development of the condition. In such cases, the implementation of progesterone testing can facilitate the discernment of anovulation [47]. Additionally, as is the case for adult women, PCOS in adolescents remains a diagnosis of exclusion, and therefore, other differential diagnoses must be ruled out. Current recommendations advocate for the identification and management of the signs of PCOS in adolescents, even in the presence of a single presumptive symptom [24][25]. The identification of adolescents at risk of PCOS will facilitate the preservation of their fertility and the prevention of the metabolic, cardiovascular, oncological, and psychiatric complications associated with this syndrome.

3.2.2. Strategies for Managing PCOS in Adolescents

In the case of adolescent females exhibiting clinical indications of PCOS, the necessity for symptomatic treatment is paramount. For those whose diagnosis is confirmed, the initial management consists of informing and educating the patient and her guardians about the disease, its risks, and its complications to ensure better compliance with treatment. Healthcare providers are obliged to ensure that explanations are clear and comprehensive, taking into account the patient’s social and cultural background. Addressing concerns regarding future fertility is imperative to ensure patient and family reassurance regarding a matter that is particularly sensitive in sub-Saharan culture.

In light of the current paucity of high-quality data, the optimal treatment protocols for PCOS must be customized to align with the clinical presentation, needs, and preferences of each patient, while also considering the potential adverse effects. Indeed, the management of PCOS comprises two components. A symptomatic component is defined as the treatment of the signs of the condition with the objective of enhancing patients’ quality of life. A prophylactic component, on the other hand, is intended to reduce the incidence of complications.

A holistic therapeutic approach encompasses lifestyle and dietary measures, pharmacological interventions, and surgical procedures, particularly in cases of infertility. Surgical interventions are not addressed in this literature review, as they are of minimal relevance to adolescents. The management of comorbidities and regular follow-up of patients are integral components of the care of adolescents with PCOS.

a) Dietary and hygiene measures

The health and dietary aspect of treatment involves implementing dietary measures and promoting regular physical activity [48], while introducing lifestyle changes that will slow down or prevent the onset of complications. This is the first therapeutic option to be applied in overweight or obese adolescents [49]. For slender adolescents, health and dietary measures should promote a healthy lifestyle and prevent excessive weight gain.

In numerous countries within the sub-Saharan region of Africa, the prevalence of obesity among women does not invariably result in adverse consequences for their mental well-being. In some instances, obesity is even regarded as an aesthetic criterion of physical attractiveness. It is therefore imperative to elucidate to patients and their guardians the benefits of weight loss and physical exercise. A 5% weight reduction has been demonstrated to regulate menstrual cycle disorders, reduce hyperandrogenism and insulin resistance, and limit cardiovascular risks [48]. To date, no study has demonstrated the superiority of one diet over another or of one form of physical exercise over another. However, extant studies have reported high relapse rates and suboptimal treatment compliance [49][50]. The following text is intended to provide a comprehensive overview of the subject matter.

Finally, various dietary supplements may be recommended, including those containing vitamin D and L-carnitine, as well as probiotics.

b) Pharmacological treatment.

The pharmacological treatment of PCOS in adolescents encompasses the use of estrogen-progestogen combinations, metformin, antiandrogens, and cosmetic interventions for acne and hirsutism. In the contemporary scientific literature, there is an increasing prevalence of reports concerning novel molecules that demonstrate variable efficacy in the metabolic management of PCOS. These include inositols, N-acetylcysteine, dipeptidyl peptidase-IV (DPP-IV) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) agonists.

Estrogen-progestins pills: In the medical management of cycle disorders in adolescents, estrogen-progestogen therapy is considered the standard of care. Beyond the regulation of menstrual cycles, these medications have been demonstrated to impede abnormal functional bleeding associated with anovulation and to ameliorate the clinical manifestations of hyperandrogenism. A notable advantage of these medications is their capacity to serve as a contraceptive method for sexually active adolescents. This attribute justifies their prescription as a primary treatment option for this demographic [51]. Furthermore, estrogen-progestogen combinations have been observed to elevate serum SHBG levels, thereby reducing excess androgens [52].

The combination of cyproterone acetate and ethinyl estradiol has also been demonstrated to reduce the skin symptoms associated with HA. The primary limitation of estrogen-progestogen therapy pertains to the potential risks of vascular and thromboembolic complications associated with its use. Estrogen-progestogen combinations containing third-generation progestogens (gestodene, desogestrel, or norgestimate) combined with ethinyl estradiol are preferred because they exhibit low androgenicity and present a minimal thrombogenic risk. In instances where estrogen-progestogen contraceptives are contraindicated, progestogen-only pills may be prescribed, given their low systemic side effects and very high contraceptive efficacy. However, these hormones do not increase serum SHBG levels and may cause weight gain [48][53].

In adolescent girls who do not require contraception and who have oligomenorrhea, it is imperative to prescribe sequential progestogens (Duphaston®) every three months, for example, for ten days, to create artificial cycles. This approach is intended to circumvent the potential for relative hyperestrogenism and thereby mitigate the risk of endometrial cancer. Prolonged use of estrogen-progestogen combinations has been associated with deficiencies in essential vitamins and minerals, primarily due to alterations in liver metabolism, reduced intestinal absorption, and increased excretion. The effects are particularly pronounced on vitamins B (B6, B9, B12), vitamin C, and vitamin E. These deficiencies may result in a range of health implications, including low energy levels, mood disorders, and diminished antioxidant protection. Furthermore, mineral imbalances, such as calcium and magnesium, have been observed to be impacted, thereby increasing the likelihood of developing bone and muscle disorders due to their augmented filtration by the kidneys. It is recommended that patients who are prescribed oral contraceptives adhere to a balanced diet in order to compensate for the aforementioned deficiencies.

Metformin: Metformin has been demonstrated to enhance the responsiveness of target cells to insulin. It has been demonstrated to reduce glucose intolerance and hyperandrogenism. In cases where the objective of treatment is to regulate menstrual cycles, estrogen-progestogen therapy is the preferred option [54]. Metformin is indicated as a first-line treatment for obese adolescents, those with glucose metabolism disorders that do not respond to lifestyle and dietary interventions, or in cases where estrogen-progestogen use is contraindicated [55]. The efficacy of metformin in adolescent girls diagnosed with PCOS and a thin body type remains to be substantiated. A recent meta-analysis of randomized controlled trials has been conducted to evaluate the efficacy of metformin and COCs in the treatment of PCOS in adolescent girls. The analysis revealed that metformin exhibited a comparable effectiveness to COCs in addressing hirsutism. Metformin was found to be superior to COCs for weight loss and improved blood glucose control; however, COCs were preferable for menstrual regulation [56].

Antiandrogens: Antiandrogens have been demonstrated to ameliorate the cutaneous manifestations associated with HA [57]. These medications function by impeding the binding of dihydrotestosterone to androgen receptors and by suppressing the activity of type 2 5α-reductase, the enzyme that catalyzes the conversion of testosterone to dihydrotestosterone in the periphery. This results in a reduction of circulating androgen levels. These hormones have been demonstrated to reduce acne and hirsutism, while also regulating menstrual cycles. In cases where estrogen-progestogen therapy has been ineffective or is contraindicated, or when patients exhibit poor tolerance to this treatment, antiandrogens are recommended as a second-line treatment option. In sexually active adolescents, the prescription of antiandrogens must be accompanied by the recommendation of contraception due to the teratogenic effects associated with these medications. The pharmaceutical agents prescribed for this group include spironolactone, cyproterone acetate, flutamide, and finasteride. Antiandrogens are generally recommended as a complementary treatment to estrogen-progestogen pills for cases of severe hirsutism, or in instances where the latter are deemed contraindicated [48].

Spironolactone, a diuretic that conserves potassium, exhibits an anti-androgenic effect, which is a therapeutic advantage in the treatment of PCOS. The mechanism of action of this pharmaceutical agent involves the inhibition of androgen receptors in target tissues, such as the skin and hair follicles. Consequently, this results in a reduction of the clinical manifestations of hyperandrogenism, including hirsutism and acne. Furthermore, it has been demonstrated to inhibit certain enzymes involved in androgen production, thereby limiting the conversion of testosterone to dihydrotestosterone (DHT). DHT is the biologically active form responsible for many androgenic effects. While spironolactone has been demonstrated to assist in the regulation of menstrual cycles by decreasing circulating androgen levels, it does not possess a direct impact on the metabolic disorders associated with PCOS, including insulin resistance and lipid imbalance. Consequently, its application must be integrated with other therapeutic modalities to ensure a comprehensive management strategy for the syndrome. It is the most frequently prescribed antiandrogen in the United States, typically following a six-month course of estrogen-progestin therapy. However, the available literature offers scant evidence to support its use in adolescents [58]-[60].

Cyproterone acetate (Androcur®) is a potent progestogen with intrinsic androgenic activity. It is primarily indicated for severe forms of HA [61]. It has been associated with an increased risk of meningioma, and therefore, it is recommended that it be replaced by another estrogen-progestogen after a maximum of 12 months of use [62]. Flutamide has demonstrated efficacy in treating hirsutism, with optimal dosages ranging from 250 to 500 milligrams administered in two divided doses per day. Its use is not widely recommended due to its high risk of hepatotoxicity compared to other antiandrogens [63]. The following text is intended to provide a comprehensive overview of the subject matter.

Finasteride, a 5α-reductase inhibitor, has been demonstrated to reduce dihydrotestosterone levels and ameliorate symptoms of hyperandrogenism. The efficacy of the treatment is restricted to cases of hirsutism or alopecia. It is classified as a second-line treatment following the failure of estrogen-progestogen and cyproterone therapies. The impact of this medication on adolescents remains under-explored, and as such, its recommendation for this demographic is not supported by substantial evidence [11].

Dermatological and cosmetic treatments

It has been documented that among adolescent patients diagnosed with PCOS; a common complaint is the presence of moderate to severe acne and hirsutism. These conditions have been demonstrated to exert a detrimental influence on patients’ quality of life, both in terms of their physical well-being and their psychological well-being. The therapeutic approach entails a multifaceted strategy aimed at reducing circulating androgen levels systemically. This involves the use of estrogen-progestogens or antiandrogens, in conjunction with lifestyle modifications and dietary interventions. However, it should be noted that these treatments have their limitations and must be accompanied by specific treatment. The therapeutic approach to acne encompasses a range of interventions, including topical treatments. In certain cases, systemic treatment may be employed. The following text is intended to provide a comprehensive overview of the subject matter.

The treatment of moderate acne has been shown to be effective with benzoyl peroxide concentrations ranging from 0.1% to 2.5% [64]. The application of this solution should be performed twice daily, following the cleansing of the face with a mild soap. For certain forms of severe inflammatory acne, cyclins, such as doxycycline, are employed as therapeutic agents [65]. It is imperative to exercise caution when considering the use of doxycycline. It is recommended that the treatment be administered in the evening, given its photosensitizing properties, and at least one hour prior to bedtime [66].

The anti-inflammatory and healing properties of zinc have been utilized in the treatment of acne. Its pharmaceutical properties make it suitable for use in the treatment of moderate acne, either as a standalone medication or in conjunction with macrolides for cases of severe acne [67]. In cases of severe, recalcitrant nodular acne, isotretinoin (Roaccutane®), a natural retinoid derived from tretinoin (or retinoic acid/vitamin A), is an anti-acne medication that is prescribed as a last resort [68]. It is imperative to note that retinoids cannot be combined with cyclins and zinc. In addition to pharmaceutical interventions, mechanical cosmetic treatments, including laser therapy, electrolysis, depilation, and hair removal, can be utilized as standalone modalities or in conjunction with medication to address hirsutism [69].

Other treatments

Myo-inositol and D-chiro-inositol

The most recent guidelines concerning PCOS, as outlined by ESHRE and ASRM, now incorporate myo-inositol and D-chiro-inositol as preferred therapeutic options for addressing infertility associated with PCOS [26]. These molecules have demonstrated encouraging results in terms of regulating menstrual cycles, enhancing ovarian function, and even increasing the chances of pregnancy in women with PCOS. Clinical studies have demonstrated the efficacy of the treatment in reducing clinical symptoms such as hirsutism and acne, which are frequently associated with hyperandrogenism.

Furthermore, the administration of myo-inositol and D-chiro-inositol has demonstrated particular efficacy in adolescent girls and young women, as it facilitates early treatment of PCOS symptoms, thereby reducing the risk of long-term complications such as infertility and metabolic disorders. However, while these molecules offer numerous advantages, it is imperative to acknowledge that their efficacy is often maximized when employed as a component of a multifaceted therapeutic strategy that incorporates a balanced diet, regular physical activity, and continuous monitoring of metabolic parameters [70][71].

N-acetylcysteine (NAC)

The use of N-acetylcysteine (NAC) in the treatment of PCOS is attracting growing interest due to its antioxidant properties and beneficial effects on the management of oxidative stress, hyperandrogenism, and insulin resistance. The restoration of balance between antioxidants and reactive oxygen species (ROS) is a critical factor in the beneficial effects of NAC. This balance is crucial for the improvement of ovarian function and the reduction of high androgen levels, as well as the enhancement of insulin sensitivity.

These effects may potentially reduce the risk of metabolic complications, such as type 2 diabetes and cardiovascular disease, which are common in patients with PCOS [72]-[74]. Recent guidelines from prominent gynecology and endocrinology societies, including ESHRE and ASRM, have recommended NAC for the management of PCOS, particularly to promote ovulation in anovulatory patients and alleviate symptoms such as hirsutism and acne [26].

A substantial corpus of clinical studies has demonstrated the efficacy of this treatment in regulating menstrual cycles and reducing free testosterone levels. While the extant evidence is encouraging, further research is necessary to confirm the long-term benefits of NAC and to refine treatment strategies, particularly with regard to dosage and the patients most likely to benefit [73][74].

Glucocorticoids

Glucocorticoids, including dexamethasone and prednisolone, are occasionally employed in the management of PCOS to mitigate hyperandrogenism by suppressing androgen production by the adrenal glands. However, their utilization is constrained by substantial adverse effects, including weight gain, hypertension, and metabolic disturbances, which renders their prolonged use less advisable [75].

Recent recommendations from prominent societies such as ESHRE and ASRM suggest that glucocorticoids should not be used as a first-line treatment. Instead, these medications should be reserved for specific cases, such as patients with congenital adrenal hyperplasia or severe insulin resistance. In such cases, they should be accompanied by comprehensive PCOS management, including lifestyle measures and other more targeted treatments.

Gonadotropin-releasing hormone agonists (GnRH-A)

GnRH agonists have been utilized in the induction of medical oophorectomy and the treatment of refractory hirsutism caused by ovarian hyperandrogenism. However, the occurrence of hypoestrogenic side effects generally necessitates the utilization of oral contraceptive pills [32][76]. Despite its efficacy, this treatment is intricate and costly.

3.2.3. Management of Comorbidities

In light of the high prevalence of these comorbidities, the ACOG, the Endocrine Society, and the European Society of Endocrinology advocate for screening for cardiovascular risk factors, performing an OGTT with 75 g of glucose (every 3 to 5 years), and evaluating for lipid abnormalities (every two years), irrespective of the patient’s age [22].

Other comorbidities may appear in adolescents with PCOS, such as depression, anxiety, eating disorders, and body dysmorphia. The presence of insulin resistance, hyperinsulinemia, and obesity should prompt investigations to rule out the onset of glucose regulation disorders or dyslipidemia. The management of PCOS must be multidisciplinary, and the care of adolescents must give way to adult care, which has its own objectives. The treatment of adolescents diagnosed with PCOS should also include the involvement of psychologists and/or psychiatrists to monitor mental health and screen for any neuropsychological complications that may arise. Consequently, further research is necessary to ascertain the frequency of mental health monitoring.